Retatrutide pipeline watch

Stay ahead of retatrutide’s next verified milestone.

Follow official clinical, regulatory, and lawful-availability developments through a clinic-focused status briefing.

Add my clinic to the status listInvestigational · Not FDA-approved · Not available for prescribing or sale

Plan early. Act only if and when the regulatory status changes.

What the list sends

A clinic-focused briefing only when there is a verified clinical, regulatory or lawful-availability change.
Nothing else: no sourcing, ordering, pricing, reservation or availability messages, ever.
No dosage, quantity, payment, patient or treatment questions are asked.
Your acknowledgement, its wording and the disclosure version are stored with your details.

Need something you can lawfully source today? Compounded semaglutide and tirzepatide pathways are assessed privately through a clinic brief. Compounded drugs are not FDA approved. Build my clinic brief

Add your clinic to the status list

Investigational · Not FDA-approved · Not available for prescribing or sale

Plan early. Act only if and when the regulatory status changes.

The regulatory statement you are acknowledging

Retatrutide is an investigational triple-receptor agonist being studied in clinical trials. It is not FDA-approved, is not available for prescribing or sale, and cannot currently be used in compounding under federal law. We do not offer, sell, source, compound, dispense, reserve, or accept orders for retatrutide. This list carries professional regulatory-status updates only. Approval and future lawful availability are not guaranteed.

Clinic or practice name

Professional role

State

Business email

NPI (optional)

10 digits, if you want it on file. Not required for status updates.

I understand this is an informational update list. It does not provide, promise, prioritize, or reserve access to retatrutide.

I agree that GLP-1 Supply Desk may contact me about this sourcing request using the contact details I provided. Consent is not a condition of any purchase.

Send me occasional professional updates about sourcing pathways and regulatory changes by email. I can unsubscribe at any time. (optional)

For licensed clinics and prescribers. Do not submit patient or medical information. Status updates only; nothing is offered, sourced, reserved or sold.

Status at a glance

Three questions, tracked separately

Clinical development, regulatory status and lawful availability each have their own record. Each one is shown as the cited sources state it, and nothing beyond them.

Clinical
Investigational
Regulatory
Not FDA-approved
Lawful availability
Not available for prescribing or sale

Solid line: the stage the status is in now
Dashed line: not reached

Current status

Investigational (Phase 3 trials sponsored by Eli Lilly and Company); not FDA-approved; not available for prescribing or sale; cannot currently be used in compounding under federal law (FDA, content current as of 2026-10-01).

Checked October 12, 2026 against the sources below. Disclosure version 2026-10-13.2.

Dated statements from the cited sources

October 1, 2026
FDA states that retatrutide cannot be used in compounding under federal law and that it is not FDA-approved.
Source: U.S. Food and Drug Administration
October 12, 2026
Phase 3 studies of retatrutide (LY3437943) sponsored by Eli Lilly and Company are listed as active or recruiting on ClinicalTrials.gov, e.g. NCT06662383 and NCT07357415.
Source: ClinicalTrials.gov (U.S. National Library of Medicine)
New entries are added only from cited sources. No date is projected.

The full statement

What you are acknowledging

Sources

Where the status comes from

Sources

FDA's concerns with unapproved GLP-1 drugs used for weight loss, U.S. Food and Drug Administration (2026-10-01)
ClinicalTrials.gov study records: retatrutide (LY3437943), ClinicalTrials.gov (U.S. National Library of Medicine) (2026-10-12)

Approval and future lawful availability are not guaranteed. This page is information for licensed clinics and prescribers, not medical advice.